SPY299.08+3.64 1.23%
DIA250.25+5.37 2.19%
IXIC9,340.22+15.63 0.17%

BMO Capital Maintains Market Perform on Fate Therapeutics, Raises Price Target to $29

BMO Capital maintains Fate Therapeutics (NASDAQ:FATE) with a Market Perform and raises the price target from $28 to $29.

Benzinga · 05/12/2020 14:24

BMO Capital maintains Fate Therapeutics (NASDAQ:FATE) with a Market Perform and raises the price target from $28 to $29.